Loading
ELF4 (ETS-related transcription factor Elf-4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer and Acute myeloid leukaemia.
Transcriptional activator that binds to DNA sequences containing the consensus 5'-WGGA-3'. Transactivates promoters of the haematopoietic growth factor genes CSF2, IL3, IL8, and of the bovine lysozyme gene. Acts synergistically with RUNX1 to transactivate the IL3 promoter.
Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.94, genetic association 0.00, somatic mutation 0.85). IntOGen calls it a driver in 2 cohorts (0 activating, 2 loss-of-function), covering Acute Myeloid Leukaemia, Low-Grade Glioma, NOS.
In plain words · ELF4 (ETS-related transcription factor Elf-4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer and Acute myeloid leukaemia.
ELF4 (ETS-related transcription factor Elf-4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer and Acute myeloid leukaemia.
Transcriptional activator that binds to DNA sequences containing the consensus 5'-WGGA-3'. Transactivates promoters of the haematopoietic growth factor genes CSF2, IL3, IL8, and of the bovine lysozyme gene.
No product in this corpus aims at ELF4 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
First described 1996. Earliest sequence paper UniProt cites for the protein: Miyazaki et al, Oncogene, 1996, "MEF, a novel transcription factor with an Elf-1 like DNA binding domain but distinct transcriptional activating properties". Source.
Sources: HGNC HGNC:3319 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q99607 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000102034 (association with cancer (MONDO_0004992) 0.66; per-cancer scores at or above 0.5: skin cancer 0.51, breast cancer 0.51 (GraphQL API, CC0)); IntOGen ELF4 (driver in 2 cohorts (Act 0, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Transcriptional activator that binds to DNA sequences containing the consensus 5'-WGGA-3'. Transactivates promoters of the haematopoietic growth factor genes CSF2, IL3, IL8, and of the bovine lysozyme gene. Acts synergistically with RUNX1 to transactivate the IL3 promoter. Transactivates the PRF1 promoter in natural killer (NK) cells and CD8+ T cells. Plays a role in the development and function of NK and NK T-cells and in innate immunity. Controls the proliferation and homing of CD8+ T-cells via the Kruppel-like factors KLF4 and KLF2. Location: Nucleus, PML body (UniProt). Locus Xq26.1 (HGNC).
Query for this target: (TITLE:"ELF4" OR ABSTRACT:"ELF4" OR TITLE:"E74 like ETS transcription factor 4" OR ABSTRACT:"E74 like ETS transcription factor 4" OR TITLE:"ETS-related transcription factor Elf-4" OR ABSTRACT:"ETS-related transcription factor Elf-4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ELF4, not a curated reading list.